瑞财经 刘治颖10月31日,新桥生物向港交所主板提交上市申请书,高盛和中信证券为联席保荐人。招股书显示,新桥生物成立于2016年,是一家采用不限治疗领域发展策略的全球性生物技术平台公司,主要专注于开发自主研发的创新型精准免疫肿瘤药物,用于癌症治疗。公司的核心产品givastomig是一种新型双特异性抗体,可同时靶向主要表达于胃癌、食管癌及胰腺癌的肿瘤抗原Claudin18.2,以及T细胞共刺激分子...
Source Link瑞财经 刘治颖10月31日,新桥生物向港交所主板提交上市申请书,高盛和中信证券为联席保荐人。招股书显示,新桥生物成立于2016年,是一家采用不限治疗领域发展策略的全球性生物技术平台公司,主要专注于开发自主研发的创新型精准免疫肿瘤药物,用于癌症治疗。公司的核心产品givastomig是一种新型双特异性抗体,可同时靶向主要表达于胃癌、食管癌及胰腺癌的肿瘤抗原Claudin18.2,以及T细胞共刺激分子...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.